EcoDrugPlus

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSKMAG00000021473
Gene Symbol: LOC108235300
3 Cross references
206 Possible Orthologues:

Receptor-Type Tyrosine-Protein Phosphatase Beta-Like

Ensembl ID : ENSKMAG00000004115
Gene Symbol: LOC108249720
2 Cross references
189 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSKMAG00000011680
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:

Renin

Ensembl ID : ENSKMAG00000016620
Gene Symbol: REN
3 Cross references
219 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSKMAG00000007897
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSKMAG00000016360
Gene Symbol: LOC108241994
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSKMAG00000019801
Gene Symbol: LOC108243261
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSKMAG00000021047
Gene Symbol: RARG
3 Cross references
353 Possible Orthologues:

Retinoic Acid Receptor Gamma-A

Ensembl ID : ENSKMAG00000017151
Gene Symbol: LOC108235710
3 Cross references
377 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSKMAG00000016751
Gene Symbol: RXRA
3 Cross references
225 Possible Orthologues:

Ribosomal Protein L10

Ensembl ID : ENSKMAG00000005017
Gene Symbol: RPL10
3 Cross references
405 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSKMAG00000007076
Gene Symbol: RPL10A
3 Cross references
366 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).